[Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
Two multicentre clinical trials of lansoprazole, a new proton pump inhibitor, were completed in patients with gastric and duodenal ulcer. Double-blind comparative studies with a beta-blocker, famotidine, in gastric ulcer (study 1) and in duodenal ulcer (study 2) were conducted. Study 1. A total of 316 cases of gastric ulcer, 158 for lansoprazole, 158 for famotidine were treated for eight weeks and the bollowing observed. Healing rates by endoscopic findings were 90% for lansoprazole and 72% for famotidine respectively, with a significant difference (p less than 0.01). Adverse events were observed in five cases in lansoprazole group, six cases in the famotidine group. Study 2. A total of 291 cases of duodenal ulcer, 148 for lansoprazole, 143 for famotidine, were treated for six weeks. Healing rates by endoscopic fendings were 92% for lansoprazole and 85% for famotidine respectively. Adverse effects were observed in 5.3% in the lansoprazole group, and 5.5% in the famotidine group.
Ogawa
N
N
Dept. of Pharmacology, School of Medicine, Ehime University.
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors; D000293:Adolescent; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy*; D015738:Famotidine / Q000008:administration & dosage / Q000627:therapeutic use; D017506:H(+)-K(+)-Exchanging ATPase; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D064747:Lansoprazole; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D013276:Stomach Ulcer / Q000188:drug therapy*
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D064747:Lansoprazole; D015738:Famotidine; D000251:Adenosine Triphosphatases; D017506:H(+)-K(+)-Exchanging ATPase; D009853:Omeprazole